Susan Hasty, Publisher
Table of Contents . . . April 19th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Drug Week | Other Publications
AIDS and HIV Therapy - Efavirenz best choice for initial antiretroviral regimen
Addiction Medicine - Repeated cocaine use impairs region of the brain that governs self-control
Infectious Disease Therapy - RFI-641 effective against respiratory syncytial virus
Kaposi Sarcoma - Matrix metalloproteinase inhibitor effective for AIDS patients
Nerve Agent Poisoning - Motion sickness drug scopolamine should be tested as new treatment
Psoriasis - Phase II study of topical alicaforsen (ISIS 2302) yields positive results
Stroke - Viagra shown effective in reducing effects
Allergic Rhinitis - FDA approves new antihistamine, Clarinex
Atherosclerosis - Lexicon Genetics discovers target for the development of drugs to treat heart disease
Bladder Incontinence - Preliminary results of transdermal oxybutynin phase IIIb trial appear positive
Depression - Antidepressant SNEC-2 begins phase I clinical trial
Finance - Isis Pharmaceuticals reports 43% increase in revenues
Generic Drugs - Company issues update regarding megestrol acetate oral suspension
Genomics - Triad Therapeutics publishes method for use of NMR in structure-based drug design
Lung Cancer - Hoag Cancer Center to launch phase II clinical trial in lung cancer vaccine
Mental Health - Data on new Alzheimer treatment presented at national meeting
New Drug Approvals - More than half of drugs approved in 2001 came from New Jersey
Parkinson Disease - Japanese firm obtains encouraging results A2A antagonist trials
Psoriasis - Research indicated that Infliximab has sustained efficacy
Pulmonary Arterial Hypertension - FDA issues approvable letter for Remodulin
Thrombocytopenia - Researchers report Argatroban benefit in acute ischemic stroke patients
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.